«Саратовский научно-медицинский журнал» » Архив номеров » Volume 9, issue 4 » Публикация

Поделиться публикацией:
Опубликовать в блог:
Опубликовано 2013-12-25 Опубликовано на SciPeople2014-06-23 11:28:14 ЖурналSaratov Journal of Medical Scientific Research


Assessment of range of uric and serum biomarkers in determination of bladder cancer severity
Popkov V.M., Ponukalin A.N. Zakharova N.B. / Антон Киселев контактное лицо
Popkov V.M., Ponukalin A.N. Zakharova N.B. Assessment of range of uric and serum biomarkers in determination of bladder cancer severity // Saratov Journal of Medical Scientific Research, Vol. 9, Issue 4, 2013, pp. 735-740
Аннотация Purpose: to establish efficiency of a range of uric and serum biomarkers of bladder cancer for diagnostics and the prognosis of risk of development of disease recurrence. Material and methods: TPA and TPS, VEGF level research in blood serum, UBC in urine in 176 people, among which 135 patients with bladder cancer (RMP) have been conducted. Group of comparison has included16 patients (patients with cystitis). The control group has been made of 25 almost healthy men. 75 patients had non-muscle invasive RMP (Ta-1N0M0). Results. It has been statistically determined that reliable growth of of TPA, TPS in blood serum and UBC in urine in patients with non-muscle invasive RMP in comparison with patients in groups of control and comparison has been established. The increase of UBC in urine of patients of this group with recurrence of tumoral growth within a year has been noted. In comparison with cytological research of urine sedimentation, molecular markers of RMP (the uric UBC and serum TPA, TPS) possess diagnostic sensitivity, allow to confirm the presence of disease, to carry out diagnostics of stages of organ and extra invasion. RMP is possible to consider as an additional prognostic serum marker increase in the VEGF level in blood serum. Conclusion. Inclusion in diagnostic process in the clinical research of biomarkers showed that identification of NMIRMP increased from 18,1% in 2006 to 55,6% in 2011. The chosen volume of complex treatment allowed to reduce recurrence and lethality in the first two years from 32 to 15,5%.
Ключевые слова публикации:
       

Нет комментариев

Вам необходимо зайти или зарегистрироваться для комментирования